Penumbra’s STORM-PE Trial Shows Superior Outcomes for CAVT Technology in Pulmonary Embolism

Key Facts

1STORM-PE trial data showed that computer assisted vacuum thrombectomy (CAVT) plus anticoagulation resulted in significantly better functional outcomes compared to anticoagulation alone.

2Patients treated with CAVT achieved greater walking distance and a higher proportion reached NYHA Class I (no physical limitations) at 90 days.

Penumbra, Inc. (NYSE: PEN) announced positive 90-day results from its STORM-PE randomized controlled trial, highlighting the clinical superiority of its Computer Assisted Vacuum Thrombectomy (CAVT) technology. The data revealed that CAVT combined with anticoagulation therapy resulted in significantly better functional outcomes for patients compared to anticoagulation alone. Patients treated with the CAVT system demonstrated improved walking capacity and a higher likelihood of reaching NYHA Class I status, indicating no physical limitations at the 90-day mark. These findings strengthen Penumbra's market position within the medical device sector and support the long-term adoption of its systems for intermediate-high risk pulmonary embolism. The robust clinical evidence is expected to serve as a bullish catalyst for the stock by bolstering insurance reimbursement arguments and driving clinical demand.